Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

KNKarun NeupaneLPLauren C. PeresLLLeslie Lauersdorf

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals elranatamab improves treatment outcomes in relapsed and refractory multiple myeloma, indicating its potential value.

Key Points

  • This research examines the real-world efficacy and safety of elranatamab in treating relapsed and refractory multiple myeloma.
  • Retrospective, single-center study conducted at Moffitt Cancer Center from October 2023 to May 2025.
  • Data collected on demographics, prior therapies, and clinical factors.
  • Analyses included logistic regression, Kaplan-Meier methods, and Cox regression for survival outcomes.
  • Overall response rate (ORR) was 52%, with median progression-free survival (PFS) of 10.1 months.
  • High marrow burden of disease adversely affected both PFS and overall survival (OS).
  • Adverse events included infections in 43% of patients, with lower rates of severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

Cite This Study

Neupane et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d179https://doi.org/10.1182/blood-2025-5833
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-32025
  2. 2Comparison of elranatamab's progression-free survival, duration of response, and overall survival from MagnetisMM-3 versus real-world external control arms: A subgroup analysis of China-predominant treatment regimens2025
  3. 3Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial2025 · 7 citations
  4. 4Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study2025
  5. 5Population Exposure–Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma2025